MA47465A - Protéines fixant le bcma, le nkg2d et le cd16 - Google Patents

Protéines fixant le bcma, le nkg2d et le cd16

Info

Publication number: MA47465A
Authority: MA; Morocco
Prior art keywords: nkg2d; proteins binding; binding bcma; bcma; proteins
Prior art date: 2017-02-10

Application number

MA047465A

Other languages

English (en)

Inventor

Gregory P Chang

Ann F Cheung

William Haney

Bradley M Lunde

Bianka Prinz

Original Assignee

Dragonfly Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-02-10

Filing date

2018-02-09

Publication date

2019-12-18

2018-02-09 Application filed by Dragonfly Therapeutics Inc filed Critical Dragonfly Therapeutics Inc

2019-12-18 Publication of MA47465A publication Critical patent/MA47465A/fr

Links

BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 title 1
108010008014 B-Cell Maturation Antigen Proteins 0.000 title 1
102000006942 B-Cell Maturation Antigen Human genes 0.000 title 1
101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 title 1
101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 title 1
101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 title 1
102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 title 1
102100022680 NKG2-D type II integral membrane protein Human genes 0.000 title 1
102000004169 proteins and genes Human genes 0.000 title 1
108090000623 proteins and genes Proteins 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

MA047465A 2017-02-10 2018-02-09 Protéines fixant le bcma, le nkg2d et le cd16 MA47465A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201762457780P	2017-02-10	2017-02-10

Publications (1)

Publication Number	Publication Date
MA47465A true MA47465A (fr)	2019-12-18

Family

ID=63107848

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA047465A MA47465A (fr)	2017-02-10	2018-02-09	Protéines fixant le bcma, le nkg2d et le cd16

Country Status (13)

Country	Link
US (1)	US20190375838A1 (fr)
EP (1)	EP3579876A4 (fr)
JP (2)	JP7257323B2 (fr)
KR (2)	KR20190115469A (fr)
CN (1)	CN110461361A (fr)
AU (1)	AU2018219348A1 (fr)
BR (1)	BR112019016424A2 (fr)
CA (1)	CA3054642A1 (fr)
IL (1)	IL268567A (fr)
MA (1)	MA47465A (fr)
MX (1)	MX2019009566A (fr)
SG (1)	SG11201907253VA (fr)
WO (1)	WO2018148566A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP6698546B2 (ja) *	2014-04-14	2020-05-27	セレクティスＣｅｌｌｅｃｔｉｓ	癌免疫療法のためのｂｃｍａ（ｃｄ２６９）特異的キメラ抗原受容体
AU2018219887B2 (en)	2017-02-08	2024-08-15	Dragonfly Therapeutics, Inc.	Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
WO2018148566A1 (fr) *	2017-02-10	2018-08-16	Adimab, Llc	Protéines fixant le bcma, le nkg2d et le cd16
BR112019017197A2 (pt)	2017-02-20	2020-04-14	Dragonfly Therapeutics Inc	proteínas que se ligam a her2, nkg2d e cd16
MX2020002036A (es) *	2017-08-23	2020-03-24	Dragonfly Therapeutics Inc	Proteinas de union a nkg2d, cd16 y un antigeno asociado al tumor.
CN112368012B (zh)	2018-02-08	2024-09-10	蜻蜓疗法股份有限公司	靶向nkg2d受体的抗体可变结构域
EA202091977A1 (ru) *	2018-05-28	2021-02-09	Драгонфлай Терапьютикс, Инк.	Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения
TW202019479A (zh) *	2018-08-08	2020-06-01	美商蜻蜓醫療公司	結合bcma、nkg2d及cd16之多特異性結合蛋白及使用方法
EP3972651A2 (fr) *	2019-05-20	2022-03-30	Novartis AG	Conjugués anticorps-médicament inhibiteurs de mcl-1 et procédés d'utilisation
AR122546A1 (es)	2020-06-05	2022-09-21	Eisai R&D Man Co Ltd	Conjugados de anticuerpo anti bcma-fármaco y métodos de uso
CN112029001B (zh) *	2020-09-02	2022-09-06	南京北恒生物科技有限公司	靶向nk激活性受体的嵌合抗原受体
US20240174768A1 (en)	2021-03-03	2024-05-30	Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus	Bispecific antibodies enhancing cell mediated immune responses
WO2024020577A2 (fr) *	2022-07-22	2024-01-25	Fred Hutchinson Cancer Center	Anticorps contre le sars-cov-2

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1909832A4 (fr) *	2005-06-29	2010-01-13	Univ Miami	Proteine de fusion anticorps-ligand de cellule immunitaire pour le traitement du cancer
EP3805269A1 (fr) *	2006-06-12	2021-04-14	Aptevo Research and Development LLC	Protéines de liaison polyvalente à chaîne unique avec une fonction effectrice
PL2235064T3 (pl) *	2008-01-07	2016-06-30	Amgen Inc	Sposób otrzymywania cząsteczek przeciwciał z heterodimerycznymi fc z zastosowaniem kierujących efektów elektrostatycznych
TW201109438A (en) *	2009-07-29	2011-03-16	Abbott Lab	Dual variable domain immunoglobulins and uses thereof
EP2306234A3 (fr) *	2009-10-02	2011-06-22	Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V.	Filtre de repliement optique, agencement de capteur à pixels et dispositif de réception numérique
EP2688909A2 (fr) *	2011-03-25	2014-01-29	Glenmark Pharmaceuticals S.A.	Immunoglobulines hétéro-dimériques
TWI679212B (zh) *	2011-11-15	2019-12-11	美商安進股份有限公司	針對ｂｃｍａ之e3以及ｃｄ３的結合分子
SG11201407963PA (en) *	2012-05-30	2015-01-29	Chugai Pharmaceutical Co Ltd	Target-tissue-specific antigen-binding molecule
EP2867253B1 (fr) *	2012-06-27	2016-09-14	F. Hoffmann-La Roche AG	Méthode de sélection et de production d'entités de ciblage personnalisées fortement sélectives et multi-spécifiques renfermant au moins deux entités de liaison différentes et leurs utilisations
WO2014122143A1 (fr) *	2013-02-05	2014-08-14	Engmab Ag	Procédé de sélection d'anticorps anti-bcma
WO2014179363A1 (fr) *	2013-04-29	2014-11-06	Adimab, Llc	Réactifs multispécificité, procédés de préparation et d'utilisation associés
WO2015197582A1 (fr) *	2014-06-27	2015-12-30	Innate Pharma	Protéines monomères multispécifiques de liaison aux antigènes
EP3172237A2 (fr) *	2014-07-21	2017-05-31	Novartis AG	Traitement du cancer au moyen d'un récepteur d'antigène chimérique anti-bcma humanisé
US10973914B2 (en) *	2015-02-20	2021-04-13	Ohio State Innovation Foundation	Bivalent antibody directed against NKG2D and tumor associated antigens
RS61907B1 (sr) *	2015-04-06	2021-06-30	Subdomain Llc	Polipeptidi koji sadrže de novo vezujući domen i njihova primena
CN109153728A (zh) *	2016-03-21	2019-01-04	埃尔斯塔治疗公司	多特异性和多功能分子及其用途
AU2018219887B2 (en) *	2017-02-08	2024-08-15	Dragonfly Therapeutics, Inc.	Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
EP3579866A4 (fr) *	2017-02-08	2020-12-09	Dragonfly Therapeutics, Inc.	Domaines variables de chaînes lourdes d'anticorps ciblant le récepteur nkg2d
WO2018148566A1 (fr) *	2017-02-10	2018-08-16	Adimab, Llc	Protéines fixant le bcma, le nkg2d et le cd16
US20200179511A1 (en) *	2017-04-28	2020-06-11	Novartis Ag	Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor

2018
- 2018-02-09 WO PCT/US2018/017653 patent/WO2018148566A1/fr unknown
- 2018-02-09 KR KR1020197026174A patent/KR20190115469A/ko not_active Application Discontinuation
- 2018-02-09 AU AU2018219348A patent/AU2018219348A1/en active Pending
- 2018-02-09 KR KR1020247004861A patent/KR20240078657A/ko unknown
- 2018-02-09 CA CA3054642A patent/CA3054642A1/fr active Pending
- 2018-02-09 MA MA047465A patent/MA47465A/fr unknown
- 2018-02-09 CN CN201880021558.4A patent/CN110461361A/zh active Pending
- 2018-02-09 MX MX2019009566A patent/MX2019009566A/es unknown
- 2018-02-09 JP JP2019543761A patent/JP7257323B2/ja active Active
- 2018-02-09 SG SG11201907253VA patent/SG11201907253VA/en unknown
- 2018-02-09 EP EP18750616.7A patent/EP3579876A4/fr active Pending
- 2018-02-09 BR BR112019016424A patent/BR112019016424A2/pt unknown
- 2018-02-09 US US16/484,936 patent/US20190375838A1/en active Pending
2019
- 2019-08-07 IL IL268567A patent/IL268567A/en unknown
2022
- 2022-12-08 JP JP2022196214A patent/JP2023029988A/ja active Pending

Also Published As

Publication number	Publication date
JP7257323B2 (ja)	2023-04-13
CN110461361A (zh)	2019-11-15
KR20190115469A (ko)	2019-10-11
AU2018219348A1 (en)	2019-08-29
CA3054642A1 (fr)	2018-08-16
RU2019127910A (ru)	2021-03-10
WO2018148566A1 (fr)	2018-08-16
SG11201907253VA (en)	2019-09-27
RU2019127910A3 (fr)	2021-06-15
EP3579876A4 (fr)	2020-11-18
EP3579876A1 (fr)	2019-12-18
MX2019009566A (es)	2020-01-20
JP2020507328A (ja)	2020-03-12
JP2023029988A (ja)	2023-03-07
KR20240078657A (ko)	2024-06-04
IL268567A (en)	2019-09-26
BR112019016424A2 (pt)	2020-04-07
US20190375838A1 (en)	2019-12-12

Publication	Publication Date	Title
MA47465A (fr)	2019-12-18	Protéines fixant le bcma, le nkg2d et le cd16
IL281305A (en)	2021-04-29	Proteins that bind CD16, NKG2D, and CCR4, EGFR, or PD-L1
IL277398A (en)	2020-11-30	PD-L1 binding epimers and related uses thereof
IL274926A (en)	2020-07-30	Pyrazolopyrimidines with activity against respiratory syncytial virus
ZA201808160B (en)	2021-08-25	Bispecific binding proteins and uses thereof
IL268755A (en)	2019-10-31	HER2, NKG2D, and CD16 binding proteins
IL268790A (en)	2019-10-31	CD33, NKG2D and CD16 binding proteins
IL270794A (en)	2020-01-30	NKG2D binding protein, CD16 and ROR1 or ROR2
MY191944A (en)	2022-07-20	Binding proteins and methods of use thereof
DK3275895T3 (da)	2021-09-27	Neuropilin-1-specifikt bindingspeptid, fusionsprotein fusioneret dermed, og anvendelse deraf
EP3515948A4 (fr)	2020-04-08	Protéines de liaison au facteur de coagulation et leurs utilisations
IL268574A (en)	2019-09-26	proteins that bind psma, nkg2d, and cd16
IL272374A (en)	2020-03-31	NKG2D, CD16, and FLT3 binding proteins
IL268768A (en)	2019-10-31	Proteins binding gd2, nkg2d and cd16
IL280512A (en)	2021-03-25	Multi-unique binding proteins that bind BCMA, NKG2D and CD16, and methods of use
EP3445394A4 (fr)	2020-02-19	Protéines de liaison à alk7 et leurs utilisations
IL268766A (en)	2019-10-31	Proteins that bind NKG2D, CD123, and CD16
GB201707248D0 (en)	2017-06-21	Modified complement proteins and uses thereof
DK3426680T3 (da)	2024-09-16	Aktivin type 2 receptor bindende proteiner og anvendelser deraf
ZA201905273B (en)	2023-06-28	Proteins binding psma, nkg2d and cd16
DK3233912T3 (da)	2021-08-02	Antistoffer, der binder human c6, og anvendelser deraf
ZA202001042B (en)	2021-05-26	Antibody specifically binding to pauf protein, and use thereof
AU2015904465A0 (en)	2015-11-12	Binding proteins, protein binding partners and uses thereof
AU2017902352A0 (en)	2017-07-06	Coagulation factor binding proteins and uses thereof
AU2016903858A0 (en)	2016-10-06	Coagulation factor binding proteins and uses thereof